Table 2.
Association of race (Black versus White) with metformin prescription across eGFR levels among patients with diabetes in Johns Hopkins Medicine
| Statistics | eGFR Category, ml/min per 1.73 m2 | |||||||
|---|---|---|---|---|---|---|---|---|
| eGFR≥90 | eGFR of 60–89 | eGFR of 45–59 | eGFR of 30–44 | |||||
| Black | White | Black | White | Black | White | Black | White | |
| Metformin prescription, % | ||||||||
| Before the FDA label change, n=11,385 | 79.1 | 78.4 | 75.2 | 76.2 | 57.2 | 63.5 | 26.1 | 42.0 |
| After the FDA label change, n=11,140 | 78.5 | 78.5 | 74.2 | 76.8 | 53.5 | 64.2 | 32.6a | 39.4 |
| Adjusted PR (95% CI), Black versus Whiteb | ||||||||
| Complete case analysis | ||||||||
| Before the FDA label change, n=6913 | 1.02 (0.99 to 1.05) | 0.98 (0.95 to 1.01) | 0.97 (0.89 to 1.05) | 0.65 (0.52 to 0.82) | ||||
| After the FDA label change, n=6705 | 1.02 (0.99 to 1.05) | 0.99 (0.96 to 1.02) | 0.92 (0.85 to 1.01) | 0.90 (0.74 to 1.09)c | ||||
| Analysis with MICE | ||||||||
| Before the FDA label change, n=11,385 | 1.02 (0.95 to 1.10) | 1.01 (0.95 to 1.09) | 0.93 (0.82 to 1.07) | 0.66 (0.52 to 0.84) | ||||
| After the FDA label change, n=11,140 | 1.01 (0.94 to 1.09) | 1.00 (0.94 to 1.08) | 0.90 (0.79 to 1.04) | 0.91 (0.73 to 1.13)c | ||||
| Analysis with average serum creatinine values | ||||||||
| Before the FDA label change, n=6913 | 1.02 (0.99 to 1.06) | 0.98 (0.95 to 1.02) | 0.95 (0.86 to 1.04) | 0.68 (0.54 to 0.87) | ||||
| After the FDA label change, n=6705 | 1.02 (0.99 to 1.05) | 0.99 (0.96 to 1.02) | 0.93 (0.86 to 1.01) | 0.85 (0.68 to 1.07) | ||||
MICE, multiple imputation by chained equations.
Prevalence of metformin use was significantly different from corresponding prevalence before the label change (P<0.05).
Adjusted for age, sex, eGFR, HbA1c, BMI, history of comorbidities (i.e., hypertension, myocardial infarction, congestive heart failure, liver disease, acidosis, hypoglycemia, and AKI), insulin use, sulfonylurea use, and other glucose-lowering agent use.
Adjusted PR after the label change was significantly different from corresponding PR before the label change (P value for interaction by period: complete case analysis =0.04, analysis with MICE =0.01, and analysis with average serum creatinine values =0.06).